Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
暂无分享,去创建一个
S. Culine | Y. Allory | G. Gravis | F. Joly | J. Fontugne | A. Fléchon | C. Chevreau | B. Laguerre | C. Pfister | A. Guillot | Valentin Harter | H. Mahammedi | C. Krucker | A. Flechon